Image of Greg Mattingly, MD From TEAM ADHD

Greg Mattingly, MD

Associate clinical professor, Washington University, St Louis, MO

Dr. Mattingly is a physician and principal investigator in clinical trials for Midwest Research Group, as well as an associate clinical professor at Washington University School of Medicine, where he teaches psychopharmacology. Dr. Mattingly has been a principal investigator in over 200 clinical trials focusing on ADHD, anxiety disorders, major depression, bipolar disorder, and schizophrenia, and has received numerous awards and distinctions for clinical leadership and neuroscience research. Dr. Mattingly currently serves on the board of directors for the American Professional Society of ADHD and Related Disorders.

Serious and Pervasive Impairments of ADHD: Altering Patient Trajectory Through Treatment

Dr. Mattingly, an associate clinical professor at Washington University School of Medicine in St. Louis, MO, discusses the consequences of untreated or inadequately treated ADHD and how early and effective treatment can change the course of this disorder.

Hello. I’m Dr Greg Mattingly, an Associate Clinical Professor at Washington University School of Medicine in St Louis, Missouri. I also serve on the Board of Directors for the American Professional Association of ADHD and Related Disorders and serve as a reviewer for the Journal of Attention Disorders.

My presentation today will document the severe consequences of untreated/inadequately treated ADHD and how early and effective treatment can change the course of this serious disorder.

The prevalence of ADHD in children and adolescents here in the United States and around the world is around 9%-11% and we know that about 4%-5% of adults will continue to have ADHD. So, it starts in childhood and tends to persist into adulthood for the majority of our patients.1-4

We used to think of ADHD being a disorder of boys. We now know that in children and adolescents, it’s about twice as common in boys as girls. In adults, it is equally common in men and women.5

The majority of our patients with ADHD don’t just have ADHD and nothing else, but frequently have ADHD comorbid with other psychiatric conditions—anxiety, tics, behavior disorders, mood disorders, and substance use disorders. In fact, comorbidity in ADHD is the rule rather than the exception.6-9

ADHD isn’t just a set of symptoms, but symptoms that dramatically impair the lives of our patients. Our ADHD patients have higher rates of comorbid psychiatric conditions, accidental injuries, academic issues, occupational issues, and relationship issues.10-15

ADHD also imparts a higher mortality rate. Studies show up to a 3-times higher risk of premature death and up to a 4- times greater risk of death from all causes in those with ADHD compared to individuals without ADHD, often due to accidents and trauma, comorbid psychiatric disorders and suicide.15-17

Of note, the risk of death significantly increased when ADHD was diagnosed at or after age 18. In addition, 82% of the individuals with ADHD who died, died most frequently as a result of unintentional injury or suicide.16-17

ADHD causes impairment across numerous domains of normal daily living. For the child, impairment is seen at school, forming peer relationships, and getting along with their family. For the adolescent and adult, impairment is reflected in increased rates of car accidents, criminal behavior, unwanted pregnancies, comorbid psychiatric conditions, substance abuse, and financial and marital issues.9,18-21

We measure the symptoms of ADHD, but how about quality of life? What do we learn when we measure the impairments that result from untreated ADHD symptoms? Untreated, our patients with ADHD have a lower quality of life. However, studies show that QoL is improved with ADHD treatment for children, adolescents, and adults. Treatment decreases ER trauma rates and emotional lability in children, and criminality in adolescents. In adults, treatment improves the ability to maintain relationships and decreases rates of depression, substance abuse, and motor vehicle accidents.22-30

There is a new approach to treatment of ADHD that is comorbid with select psychiatric disorders. The old approach was to treat the most serious disorder first. ADHD was often considered a secondary condition and maybe not as impairing. Now, the new approach is to treat ADHD aggressively and appropriately—treat ADHD and also treat other psychiatric conditions at the same time, so an emerging holistic model of treatment.31

Thank you very much for your attention, and on behalf of TEAM ADHD, I appreciate you being part of this educational initiative.

REFERENCES: 1.Fayyad J, et al. The descriptive epidemiology of DSM-IV Adult ADHD in the World Health Organization World Mental Health Surveys. Atten Defic Hyperact Disord. 2017;9(1):47- 65. 2.Visser SN, et al. Trends in the parent-report of health care provider diagnosed and medicated attention deficit/hyperactivity disorder: United States, 2003-2011. J Am Acad Child Adolesc Psychiatry. 2014;53(1):34-46. 3. Merikangas KR, et al. Lifetime prevalence of mental disorders in US adolescents: results from the National Comorbidity Survey Replication. Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry.2010;49(10):980-989. 4. Kessler RC, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723. 5. Faraone SV, et al. Attention- deficit/hyperactivity disorder. Nat Rev Dis Primers. 2015;1:15020. 6. Banaschewski T, et al. Attention- deficit/hyperactivity disorder. Dtsch Arztebl Int. 2017;114(9):149-159. 7. MTA Cooperative Group. A 14- month randomized clinical trial of treatment strategies for attention- deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56(12):1073-1086. 8. Jensen CM, Steinhausen HC. Comorbid mental disorders in children and adolescents with attention-deficit/hyperactivity disorder in a large nationwide study. Atten Defic Hyperact Disord.2015;7(1):27-38. 9. Caye A, et al. Attention- deficit/hyperactivity disorder trajectories from childhood to young adulthood: evidence from a birth cohort supporting a late-onset syndrome. JAMA Psych. 2016;73(7):705-712. 10. Clemow DB, et al. A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities. Neuropsychiatr Dis Treat. 2017;13:357-371. 11. Dalsgaard S, et al. Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry. 2015;2(8):702-709. 12. Chien WC, et al. The risk of injury in adults with attention-deficit hyperactivity disorder: a nationwide, matched cohort, population-based study in Taiwan. Res Dev Disabil. 2017;65:57-73. 13. Mattingly GW, Anderson RH. Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems. CNS Spectr. 2016;21(S1):45-59. 14. Mattingly GW, et al. A clinician’s guide to ADHD treatment options. Postgrad Med. 2017;129(7):657-666. 15. Dalsgaard S, et al. Mortality in children, adolescents, and adults with attention deficit hyperactivitydisorder: a nationwide cohort study. Lancet. 2015;385(9983):2190-2196. 16. London AS, Landes SD. Attention deficit hyperactivity disorder and adult mortality. Prev Med. 2016;90:8- 10. 17. Sun S et al. Association of psychiatric comorbidity with the risk of premature death among children and adults with attention- deficit/hyperactivity disorder. JAMA Psychiatry. 2019 Aug 7. doi: 10.1001. 18. Galera C et al. Childhood and adolescent hyperactivity-inattention symptoms and academic achievement 8 years later: the GAZEL Youth study. Psychol Med. 2009;39(11):1895-1906. 19. Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child 2005;90 (suppl 1):i2-i7. 20. Brook JS, et al. Adolescent ADHD and adult physical and mental health, work performance, and financial stress. Pediatrics. 2013;131(1):5-13. 21. Biederman J, et al. Functional impairments in adults with self- reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry. 2006;67(4):524-540. 22. Banaschewski T, et al. Health-related quality of life and functionaloutcomes from a randomized withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder. CNS Drugs.2014;28(12):1191-1203. 23. Agarwal R, et al. The quality of lifeof adults with attention deficit hyperactivity disorder: a systematic review. Innov Clin Neurosci. 2012;9(5- 6):10-21. 24. Berek M, et al. Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS(R) MPH: is treatment response different between children and adolescents? Child Adolesc Psychiatry Ment Health. 2011;5:26. 25. Winters DE, et al. Improvements inirritability with open-labelmethylphenidate treatment in youth with comorbid attention deficit/hyperactivity disorder and disruptive mood dysregulation disorder. J Child Adolesc Psychopharmacol. 2018;28(5):298-305. 26. Blader JC, et al. Prevalence and treatment outcomes of persistent negative mood among children with attention-deficit/hyperactivity disorder and aggressive behavior. J Child Adolesc Psychopharmacol. 2016(2);26(2):164-173. 27. Lichtenstein P, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med. 2012;367(21):2006-2014. 28. Chang, Z, et al. Medication for Attention-Deficit/Hyperactivity Disorder and risk for depression: a nationwide longitudinal cohort study. Biol Psychiatry. 2016;80(12):916-922. 29. Chang Z, et al. Stimulant ADHD medication and risk for substance abuse. J. Child Psychol Psychiatry.2014;55(8);878-885. 30. Chang Z, et al. Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry.2017;74(6):597-603. 31. Faraone SV, Asherson P, Banaschewski T, et al. Attention- deficit/hyperactivity disorder. Nat Rev Dis Primers. 2015;1:15020. 32. Mattingly GW, Anderson RH. Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems. CNS Spectr. 2016;21(S1):45-59.

Image: A New Approach to ADHD News

TEAM ADHD Updates: A New Approach to ADHD Featuring Greg Mattingly, MD

Download